Home›Trial›NCT06634420
🔬NCT06634420Phase 3ACTIVE NOT RECRUITING

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

Study Summary

This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.

Conditions
Hereditary Angioedema
Interventions / Drugs
NTLA-2002Normal Saline IV Administration
View on ClinicalTrials.gov ↗
Sponsor
NTLA
Intellia Therapeutics
Gene Editing
D44/100
Study Details
Enrollment60 participants
Primary Completion—
Lead SponsorIntellia Therapeutics
Data Retrieved2026-04-11 04:23:01.073777+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.